Currently, no PI3K inhibitors have been approved specifically for neuroinflammatory diseases, though several agents, such as duvelisib and copanlisib (for cancer), are in advanced clinical trials and could potentially be repurposed for CNS diseases [181]. The gene discussed is PIK3CA; the disease is cancer.